Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

gation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation, Inc.

Web site: http://www.medivation.com//

Ticker Symbol: (NASDAQ-NMS:MDVN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:12/3/2009)...VIEW, Calif., Dec. 3 Om... of medication system solutions to acute healthcar...thCare System (CHS), the largest healthcare syste...blic system in the nation, has chosen Omnicell Omn... (ADCs) to streamline management of medications in...
(Date:12/3/2009)... Dec. 3 MicroCHIPS, a developer of...nounced it has been named a 2010 Technology Pionee... was selected for pioneering a novel medical devic... designed to bridge the gap between disease monito... broad applicability, from ,rescue, applications i...
(Date:12/3/2009)... Dec. 3 Instacare Corp. ...life-saving prescription drugs, home testing produ... provider of direct to patient diabetes programs a...d revolutionary cell phone centric technologies an...iple updated and enhanced patent and trademark app...
Breaking Medicine Technology:Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 2Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 3Omnicell Selected by Nation's Third Largest Public Healthcare System for Medication Management Systems 4MicroCHIPS Named 2010 Technology Pioneer by World Economic Forum 2Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products 2Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products 3New Tests Spot Tough to Detect Cancers Sooner 47808 1New Tests Spot Tough to Detect Cancers Sooner 47808 2Hospitalized patients need better understanding of CPR and outcomes 47805 1Hospitalized patients need better understanding of CPR and outcomes 47805 2Hospitalized patients need better understanding of CPR and outcomes 47805 3Scientists unravel the mystery of white nose syndrome 8708 1Scientists unravel the mystery of white nose syndrome 8708 2Scientists unravel the mystery of white nose syndrome 8708 3
... - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC...ted patient enrolment in a Phase 2 clinical trial ... combination with paclitaxel and carboplatin in pa...h K-RAS or EGFR-activated tumours. The Principal I...sor, Division of Hematology/Oncology and Departmen...
...eing issued by Coast IRB: In a press release is...lic that it had discovered what appeared to be a f...dent review board for evaluation. Coast IRB has s...tly commenced as part of a congressional "sting" o...use Subcommittee on Oversight and Investigations o...
Other Medicine Technology:Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Congressional 'Sting' Operation Uncovered By Coast IRB 2
(Date:12/3/2009)...ithout need to fly far for food, wing shapes chang..., Dec. 3 (HealthDay News) -- Many people think evo... but it can happen much faster and new research sh...n winter appears to be having an effect on a popul...r findings in the Dec. 3 online edition of Curren...
(Date:12/3/2009)..., , WASHINGTON, Dec. 3 /PRNewswire-USNewswir...use and Public Campaign: ,, U.S. Senate Judicia...ering an amendment to the health care reform bill ...legal exemptions for violations such as price fixi...ce industry fiercely opposes the repeal, which wou...
(Date:12/3/2009)... The relatively low number of new cases created by...tigation strategies such as vaccination, social di...o lessen the final impact of the virus, suggests a....ca/cgi/doi/10.1503/cmaj.091807 reported in CMA...maj.ca . , The study looked at data from labora...
(Date:12/3/2009)... Each year, editors of the...octors on its editorial board, choose the top 10 h...ems on the list for 2009. , ...ditors of the Harvard Health Letter , in consulta...se the top 10 health stories of the year. Here are...
(Date:12/3/2009)... Henninger,s creative staf...rds for full production work and 5 awards for post...PRWEB) December 3, 2009 -- The 13th Annual TIVA Pe...squo;s best at the National Press Club in Washingt...quo;Henninger”) capped off a successful year...
Breaking Medicine News(10 mins):Health News:Feeding Birds in Winter Could Speed Evolution of Species 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 3Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 4Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 5Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 6Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 7Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 8Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:The Top Health Stories Of 2009, From The Harvard Health Letter 2Health News:The Top Health Stories Of 2009, From The Harvard Health Letter 3Health News:The Top Health Stories Of 2009, From The Harvard Health Letter 4Health News:Henninger Media Services Wins 9 TIVA Peer Awards 2Health News:Henninger Media Services Wins 9 TIVA Peer Awards 3
...y be synonymous with milder weather and opening da...Y, a 15-year-old baseball player and sophomore at ...to shut out cancer. , , Mele, a catcher and third...ute Myelogenous Leukemia (AML), a fast-growing can...
...(Nasdaq: GPRO ) announced today that the Company...he Ltd. and Roche Molecular Systems, Inc., has pre... concerning the Company,s supply and purchase agre...pute Resolution issued an interim award that dismi...
...nic Touch(TM) hearing aid is smallest receiver-in-... 1 Sonic Innovations, Inc. (Nasdaq: SNCI ) will...ice, Sonic Touch(TM), at the Audiology NOW! Confer...t available in the market. , , Sonic Touch(TM) i...
...ax Inc. (Nasdaq: NVAX) announced today that ...12.5 million shares of Novavax,s common stock at $...ila Pharmaceuticals as part of the new strategic a... convertible notes due in July 2009 and for a vari...
... for disease therapy, researchers say , , ...on in protein folding contributes to nerve cell de...elp lead to new treatments, Dutch researchers repo...nfolded protein response" typically protects cells...
...he Ribbon Cutting Ceremony, this past Friday, hono...ool of Nursing West Chester campus was a proud and...aff, and students. , , (Photo: http://www.ne... of Hondros College , provided an inspiring speec...
Other Medicine News:Health News:Blood, Marrow Drive Offers Hope for Baseball Player, 15 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 2Health News:Gen-Probe, Roche Prevail in Arbitration With Digene Concerning Human Papillomavirus Agreement 3Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 2Health News:Sonic Innovations Celebrates Company's First Receiver-In-Canal Hearing Aid 3Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:Protein-Folding Problem May Help Spur Alzheimer's 2Health News:Hondros College School of Nursing West Chester Campus Opens New Building; Honors Nursing Administrators 2Health News:Hondros College School of Nursing West Chester Campus Opens New Building; Honors Nursing Administrators 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: